ArticleClinical hypertension2022

A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy.

Eun-Seok Jeon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.